Trial Information

Evaluation, Treatment and Training Protocol for Patients With Bone Marrow Failure States, Isolated or Multilineage Cytopenias, Metastatic Solid Tumors, or Hematologic Malignancies

This protocol is designed to allow the evaluation, follow up, and standard medical care of
patients (and when appropriate, their stem cell donor) with bone marrow failure states,
cytopenias, metastatic solid tumors, or hematologic malignancies not currently entered on an
active NHLBI Hematology Branch protocol or not being screened for an active NHLBI research
protocol. Its purpose is to allow investigation into the hematologic problems of these
patients for the primary purpose of teaching and furthering general hematologic knowledge.
The ability to evaluate and treat patients with a wide variety of hematologic disease is
critical to maintaining our accreditation as a hematology fellowship program and training
our fellows to be competent hematologists, as well as for keeping all staff, including
senior staff, up-to-date and familiar with the evaluation and treatment of patients with a
wide spectrum of hematologic disease. It also allows the Hematology Branch to evaluate
patients referred with rare or as yet undiagnosed hematologic problems, both potentially
benefiting the patient and stimulating new research directions for the Hematology Branch in
the future. Periodic follow-up and treatment of patients previously entered on Hematology
Branch protocols in order to monitor the long-term course of the underlying hematologic
state and the consequences of experimental treatments is also required for fellowship
training, and for maintenance of good referral relationships with patients and their
physicians.